| Vivian Partida, DO | |
|
Us Hwy 491 North, Shiprock, NM 87420 | |
| (505) 368-6001 | |
| Not Available |
| Full Name | Vivian Partida |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 6 Years |
| Location | Us Hwy 491 North, Shiprock, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306349188 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 17996 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northern Navajo Medical Center | Shiprock, NM | Hospital |
| San Juan Regional Medical Center | Farmington, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dhhs Phs Naihs Shiprock Hospital | 0749193837 | 93 |
News Archive
Two new studies show an increase in polyp detection rates using the Third Eye Retroscope (TER), a retrograde viewing device, during colonoscopy. The first study found that TER added to standard colonoscopy detected 13.2 percent more polyps than colonoscopy alone, including 11 percent additional adenomas (precancerous polyps). A second study examined endoscopist experience using TER and its impact on polyp detection rates, concluding that polyp detection rates improved significantly with TER.
Postoperative pain can pose a number of challenges for surgical patients and their care providers. A common method to treat pain has been to administer opioids.
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved.
› Verified 5 days ago
| Entity Name | Dhhs Phs Naihs Shiprock Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780639971 PECOS PAC ID: 0749193837 Enrollment ID: O20031105000809 |
News Archive
Two new studies show an increase in polyp detection rates using the Third Eye Retroscope (TER), a retrograde viewing device, during colonoscopy. The first study found that TER added to standard colonoscopy detected 13.2 percent more polyps than colonoscopy alone, including 11 percent additional adenomas (precancerous polyps). A second study examined endoscopist experience using TER and its impact on polyp detection rates, concluding that polyp detection rates improved significantly with TER.
Postoperative pain can pose a number of challenges for surgical patients and their care providers. A common method to treat pain has been to administer opioids.
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vivian Partida, DO Po Box 160, Shiprock, NM 87420-0160 Ph: (505) 368-6001 | Vivian Partida, DO Us Hwy 491 North, Shiprock, NM 87420 Ph: (505) 368-6001 |
News Archive
Two new studies show an increase in polyp detection rates using the Third Eye Retroscope (TER), a retrograde viewing device, during colonoscopy. The first study found that TER added to standard colonoscopy detected 13.2 percent more polyps than colonoscopy alone, including 11 percent additional adenomas (precancerous polyps). A second study examined endoscopist experience using TER and its impact on polyp detection rates, concluding that polyp detection rates improved significantly with TER.
Postoperative pain can pose a number of challenges for surgical patients and their care providers. A common method to treat pain has been to administer opioids.
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
Regado Biosciences, a privately held company leading the development of antithrombotic therapeutic aptamers with active control agents, announced that on September 8, 2009 enrollment of the first patient in a Phase 2b, randomized, partially-blinded, multi-center, active-controlled, dose-ranging study of its lead product candidate, the REG1 anticoagulation system (REG1) was achieved.
› Verified 5 days ago
Adekunle Gbadegesin Kuku, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: Us Hwy 491 North, Shiprock, NM 87420 Phone: 505-368-6401 Fax: 505-368-6431 | |
Dr. Patrick William Murphy, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Us Highway 491 North, Northern Navajo Medical Center, Shiprock, NM 87420 Phone: 505-368-6001 Fax: 505-368-7011 | |
Dr. Brianna Joy Cowan, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: Us Hwy 491 North, Shiprock, NM 87420 Phone: 505-368-6001 | |
Alyssa M Finlay, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: Highway 491 North, Shiprock, NM 87240 Phone: 505-368-6401 Fax: 505-368-6431 | |
Ryan Jean Kronen, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Us Hwy 491 N, Shiprock, NM 87420 Phone: 505-368-7050 Fax: 505-368-6025 | |
Joyanna Wendt, MD, MPH Internal Medicine Medicare: Medicare Enrolled Practice Location: Us Hwy 491 North, Shiprock, NM 87420 Phone: 505-368-7066 | |
Dr. Daniel Burke, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Northern Navajo Medical Center, Us Hwy 491, Shiprock, NM 87420 Phone: 505-368-6001 |